DOCSLIB.ORG

Quantitative Analysis of New Generation Antidepressants Using Gas Chromatography-Mass Spectrometry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quantitative Analysis of New Generation Antidepressants Using Gas Chromatography-Mass Spectrometry Ghent University Faculty of Pharmaceutical Sciences Quantitative analysis of new generation antidepressants using gas chromatography-mass spectrometry Applications in clinical and forensic toxicology Sarah Wille Pharmacist Thesis submitted to obtain the degree of Doctor in Pharmaceutical Sciences 2008 Dean: Promoter : Prof. Dr. Jean-Paul Remon Prof. Dr. Willy Lambert TABLE OF CONTENTS Table of contents Acknowledgements Copyright List of Abbreviations Structure Chapter I Introduction 1 Depression, use of antidepressants, and relevance of antidepressant monitoring I.1. Foreword 3 I.2. Onset of depression 3 I.3. Action mechanisms of antidepressants 4 I.3.1. Activation of transcription factors 5 I.3.2. Activation of neurotropic pathways 7 I.3.3. Increasing neurogenesis 8 I.4. Classification of antidepressants 8 I.5. Side-effects, drug-drug interactions and toxicity 10 I.6. Relevance of Therapeutic Drug Monitoring 13 I.7. Selection of antidepressants and relevant issues for TDM 14 I.7.1. Citalopram 15 I.7.1.1. Mechanism of action 16 I.7.1.2. Pharmacokinetics 16 I.7.1.3. Drug concentrations and clinical effects 17 I.7.1.4. Drug interactions, side-effects and toxicity 18 I.7.1.5. Analytical Methods 18 I.7.2. Fluoxetine 19 I.7.2.1. Mechanism of action 20 I.7.2.2. Pharmacokinetics 20 I.7.2.3. Drug concentrations and clinical effects 21 I.7.2.4. Drug interactions, side-effects and toxicity 22 I.7.2.5. Analytical Methods 22 I.7.3. Fluvoxamine 23 I.7.3.1. Mechanism of action 24 I.7.3.2. Pharmacokinetics 24 I.7.3.3. Drug concentrations and clinical effects 25 I.7.3.4. Drug interactions, side-effects and toxicity 25 I.7.3.5. Analytical Methods 26 I.7.4. Maprotiline 27 I.7.4.1. Mechanism of action 27 I.7.4.2. Pharmacokinetics 28 I.7.4.3. Drug concentrations and clinical effects 28 I.7.4.4. Drug interactions, side-effects and toxicity 28 I.7.4.5. Analytical Methods 29 I.7.5. Melitracen 30 I.7.6. Mianserin 30 I.7.6.1. Mechanism of action 31 I.7.6.2. Pharmacokinetics 31 I.7.6.3. Drug concentrations and clinical effects 31 I.7.6.4. Drug interactions, side-effects and toxicity 32 I.7.6.5. Analytical Methods 32 I.7.7. Mirtazapine 32 I.7.7.1. Mechanism of action 33 I.7.7.2. Pharmacokinetics 33 I.7.7.3. Drug concentrations and clinical effects 33 I.7.7.4. Drug interactions, side-effects and toxicity 34 I.7.7.5. Analytical Methods 35 I.7.8. Paroxetine 35 I.7.8.1. Mechanism of action 36 I.7.8.2. Pharmacokinetics 36 I.7.8.3. Drug concentrations and clinical effects 37 I.7.8.4. Drug interactions, side-effects and toxicity 38 I.7.8.5. Analytical Methods 38 I.7.9. Reboxetine 39 I.7.9.1. Mechanism of action 40 I.7.9.2. Pharmacokinetics 40 I.7.9.3. Drug concentrations and clinical effects 40 I.7.9.4. Drug interactions, side-effects and toxicity 41 I.7.9.5. Analytical Methods 41 I.7.10. Sertraline 42 I.7.10.1. Mechanism of action 42 I.7.10.2. Pharmacokinetics 42 I.7.10.3. Drug concentrations and clinical effects 43 I.7.10.4. Drug interactions, side-effects and toxicity 44 I.7.10.5. Analytical Methods 44 I.7.11. Trazodone 45 I.7.11.1. Mechanism of action 45 I.7.11.2. Pharmacokinetics 45 I.7.11.3. Drug concentrations and clinical effects 46 I.7.11.4. Drug interactions, side-effects and toxicity 46 I.7.11.5. Analytical Methods 47 I.7.12. Venlafaxine 48 I.7.12.1. Mechanism of action 48 I.7.12.2. Pharmacokinetics 49 I.7.12.3. Drug concentrations and clinical effects 49 I.7.12.4. Drug interactions, side-effects and toxicity 50 I.7.12.5. Analytical Methods 51 I.7.13. Viloxazine 51 I.7.13.1. Mechanism of action 52 I.7.13.2. Pharmacokinetics 52 I.7.13.3. Drug concentrations and clinical effects 52 I.7.13.4. Drug interactions, side-effects and toxicity 52 I.7.13.5. Analytical Methods 53 I.8. Relevance of antidepressant analysis in forensic toxicology 53 I.9. References 54 Chapter II Objectives 75 Chapter III Sample preparation 79 Development and optimization of a solid phase extraction procedure for several biological matrices III.1. Introduction 81 III.2. Experimental 82 III.2.1. Reagents 82 III.2.2. Stock solutions 83 III.2.3. Mixer, sonicator, vacuum manifold, evaporator 84 and centrifuge III.2.4. High Pressure Liquid Chromatography (HPLC) 85 III.2.5. Gas chromatography-Mass spectrometry (GC-MS) 85 III.3. Solid phase extraction development 87 III.3.1. Choice of SPE sorbent 87 III.3.2. Choice of loading, washing and eluting conditions 90 III.3.3. Final SPE method of ADs spiked in water samples 93 III.4. Optimization of the SPE procedure for extraction of ADs 95 from biological matrices III.4.1. SPE optimization for plasma samples 96 III.4.2. SPE optimization for blood samples 98 III.4.3. SPE optimization for brain samples 99 III.4.4. SPE optimization for hair samples 100 III.4.5. Recovery of ADs using SPE from plasma, blood 103 brain tissue III.5. Conclusion 104 III.6. References 106 Chapter IV Derivatization 109 Development and optimization of a solid phase extraction procedure for several biological matrices IV.1. Introduction 111 IV.2. Experimental 114 IV.2.1. Reagents 114 IV.2.2. Preparation of standard solutions 114 IV.2.3. Instrumentation 115 IV.2.4. Gas chromatographic parameters 115 IV.2.5. Mass spectrometric parameters 116 IV.3. Acetylation 116 IV.3.1. Optimization of acetylation reaction 116 IV.3.2. Acetylation reaction with antidepressants 116 IV.3.2.1. ADs containing an alcohol function 117 IV.3.2.2. ADs containing a primary amine function 119 IV.3.2.3. ADs containing secondary amine functions 121 IV.3.2.4. Tertiary amines 122 IV.3.3. Conclusion 123 IV.4. Heptafluorobutyrylation 124 IV.4.1. Optimization of HFBI reaction 124 IV.4.1.1. Experimental 124 IV.4.1.2. Results 124 IV.4.2. Optimization of HFBA reaction 126 IV.4.2.1. Experimental 126 IV.4.2.2. Results 126 IV.4.3. Heptafluorobutyrylation of antidepressants 127 IV.4.3.1. ADs containing an alcohol function 128 IV.4.3.2. ADs containing a primary amine function 130 IV.4.3.3. ADs containing secondary amine functions 130 IV.4.3.4. Tertiary amines 131 IV.4.4. Conclusion 131 IV.5. Choice of acylation procedure 133 IV.5.1. Acetylation versus heptafluorobutyrylation 133 IV.5.2. Heptafluorobutyrylimidazole versus heptafluoro- 134 butyric anhydride IV.5.2.1. Experimental 134 IV.5.2.2. Results 134 IV.5.3. Conclusion 136 IV.6. Final derivatization procedure 137 IV.7. Validation of final derivatization procedure 137 IV.7.1. Precision 137 IV.7.1.1. Experimental 137 IV.7.1.2. Results 137 IV.7.2. Linearity 138 IV.7.2.1. Experimental 138 IV.7.2.2. Results 138 IV.7.3. Stability of the derivatives 139 IV.7.3.1. Experimental 139 IV.7.3.2. Results 139 IV.8. Conclusion 141 IV.9. References 142 Chapter V Gas chromatographic-mass spectrometric 145 method development V.1. Introduction 147 V.2. Experimental 148 V.2.1. Reagents 148 V.2.2. Stock solutions 149 V.2.3. Equipment 149 V.3. Gas chromatographic parameters 150 V.3.1. Sample introduction 150 V.3.1.1. Cold on-column versus split/splitless injection 150 V.3.1.2. Splitless injection optimization 152 V.3.2. Chromatographic separation 157 V.3.2.1. Column choice 158 V.3.2.2. Choice of carrier gas and flow rate 159 V.3.2.3. Optimization of temperature program 159 V.3.3. Internal standard choice 162 V.3.4. Conclusion: gas chromatographic method 163 V.4. Mass spectrometric parameters 164 V.4.1. Optimization of mass selective detector parameters 167 V.4.2. Spectra of the derivatized ADs after electron 168 ionization V.4.2.1. Venlafaxine and O-desmethylvenlafaxine 168 V.4.2.2. Viloxazine 170 V.4.2.3. Fluvoxamine 171 V.4.2.4. Fluoxetine, fluoxetine-d6 and desmethylfluoxetine 172 V.4.2.5. Mianserin, mianserin-d3 and desmethylmianserin 175 V.4.2.6. Mirtazapine and desmethylmirtazapine 177 V.4.2.7. Melitracen 179 V.4.2.8. Reboxetine 179 V.4.2.9. Citalopram, desmethylcitalopram and dides- 180 methylcitalopram V.4.2.10. Maprotiline and desmethylmaprotiline 182 V.4.2.11. Sertraline and desmethylsertraline 184 V.4.2.12. Paroxetine and paroxetine-d6 185 V.4.2.13. Trazodone and m-chlorophenylpiperazine 186 V.4.3. Spectra of the derivatized ADs after positive ion 188 chemical ionization V.4.3.1. Venlafaxine and O-desmethylvenlafaxine 190 V.4.3.2. Viloxazine 192 V.4.3.3. Fluvoxamine 192 V.4.3.4. Fluoxetine, fluoxetine-d6 and desmethylfluoxetine 193 V.4.3.5. Mianserin, mianserin-d3 and desmethylmianserin 196 V.4.3.6. Mirtazapine and desmethylmirtazapine 198 V.4.3.7. Melitracen 199 V.4.3.8. Reboxetine 200 V.4.3.9. Citalopram, desmethylcitalopram and dides- 201 methylcitalopram V.4.3.10. Maprotiline and desmethylmaprotiline 204 V.4.3.11. Sertraline and desmethylsertraline 206 V.4.3.12. Paroxetine and paroxetine-d6 207 V.4.3.13.
Load more

Recommended publications
  • Impact of CYP2C19 Genotype on Sertraline Exposure in 1200 Scandinavian Patients
    www.nature.com/npp ARTICLE Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients Line S. Bråten 1,2, Tore Haslemo1,2, Marin M. Jukic3,4, Magnus Ingelman-Sundberg 3, Espen Molden1,5 and Marianne K. Kringen1,2 Sertraline is an (SSRI-)antidepressant metabolized by the polymorphic CYP2C19 enzyme. The aim of this study was to investigate the impact of CYP2C19 genotype on the serum concentrations of sertraline in a large patient population. Second, the proportions of patients in the various CYP2C19 genotype-defined subgroups obtaining serum concentrations outside the therapeutic range of sertraline were assessed. A total of 2190 sertraline serum concentration measurements from 1202 patients were included retrospectively from the drug monitoring database at Diakonhjemmet Hospital in Oslo. The patients were divided into CYP2C19 genotype-predicted phenotype subgroups, i.e. normal (NMs), ultra rapid (UMs), intermediate (IMs), and poor metabolisers (PMs). The differences in dose-harmonized serum concentrations of sertraline and N-desmethylsertraline-to-sertraline metabolic ratio were compared between the subgroups, with CYP2C19 NMs set as reference. The patient proportions outside the therapeutic concentration range were also compared between the subgroups with NMs defined as reference. Compared with the CYP2C19 NMs, the sertraline serum concentration was increased 1.38-fold (95% CI 1.26–1.50) and 2.68-fold (95% CI 2.16–3.31) in CYP2C19 IMs and PMs, respectively (p < 0.001), while only a marginally lower serum concentration (−10%) was observed in CYP2C19 UMs (p = 0.012). The odds ratio for having a sertraline concentration above the therapeutic reference range was 1.97 (95% CI 1.21–3.21, p = 0.064) and 8.69 (95% CI 3.88–19.19, p < 0.001) higher for IMs and PMs vs.
    [Show full text]
  • ZOLOFT® 50 Mg and 100 Mg Tablets
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME ZOLOFT® 50 mg and 100 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 50 mg tablet contains sertraline hydrochloride equivalent to 50 mg sertraline. Each 100 mg tablet contains sertraline hydrochloride equivalent to 100 mg sertraline. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM ZOLOFT 50 mg tablets: white film-coated tablets marked with the Pfizer logo on one side and “ZLT” scoreline “50” on the other. Approximate tooling dimensions are 1.03 cm x 0.42 cm x 0.36 cm. ZOLOFT 100 mg tablets: white film-coated tablets marked with the Pfizer logo on one side and “ZLT-100” or “ZLT 100” on the other. Approximate tooling dimensions are 1.31 cm x 0.52 cm x 0.44 cm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Adults ZOLOFT is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. Following satisfactory response, continuation with ZOLOFT therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes. ZOLOFT is indicated for the treatment of obsessive compulsive disorder (OCD). Following initial response, sertraline has been associated with sustained efficacy, safety and tolerability in up 2 years of treatment of OCD. ZOLOFT is indicated for the treatment of panic disorder, with or without agoraphobia. ZOLOFT is indicated for the treatment of post-traumatic stress disorder (PTSD). ZOLOFT is indicated for the treatment of social phobia (social anxiety disorder).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0203752 A1 Blough Et Al
    US 201302O3752A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0203752 A1 Blough et al. (43) Pub. Date: Aug. 8, 2013 (54) PHENYLMORPHOLINES AND ANALOGUES Publication Classification THEREOF (51) Int. Cl. (76) Inventors: Bruce E. Blough, Raleigh, NC (US); C07D 265/30 (2006.01) Richard Rothman, Ellicott City, MD (52) U.S. Cl. (US); Antonio Landavazo, Raleigh, NC CPC .................................... C07D 265/30 (2013.01) (US); Kevin M. Page, Willow Spring, USPC ......... 514/231.2: 544/106; 544/174: 544/163 NC (US); Ann Marie Decker, Durham, NC (US) (57) ABSTRACT (21) Appl. No.: 13/698,892 Provided herein are compounds and prodrugs and methods of (22) PCT Filed: May 20, 2011 preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or (86). PCT No.: PCT/US2011/037361 more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceu S371 (c)(1), tical compositipos1u1ons compris1ng one or more OIf uneseth com (2), (4) Date: Mar. 4, 2013 pounds or prodrugs, which may further comprise one or more Related U.S. Application Data additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to (60) Provisional application No. 61/347,259, filed on May modification of monoamine neutrotransmitter levels, such as 21, 2010. pre-obesity, obesity, addiction, and depression. US 2013/0203752 A1 Aug. 8, 2013 PHENYLMORPHOLINES AND ANALOGUES 0006 Another anorectic, which was prescribed for the THEREOF short-term treatment of obesity, is phenmetrazine Phenmetra Zine is reportedly a potent Substrate for norephinephrine and FEDERALLY SPONSORED RESEARCHOR dopamine transporters and displays stimulant properties DEVELOPMENT similar to those of amphetamines.
    [Show full text]
  • Use of Human Plasma Samples to Identify Circulating Drug Metabolites That Inhibit Cytochrome P450 Enzymes
    1521-009X/44/8/1217–1228$25.00 http://dx.doi.org/10.1124/dmd.116.071084 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:1217–1228, August 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes Heather Eng and R. Scott Obach Pfizer Inc., Groton, Connecticut Received April 19, 2016; accepted June 3, 2016 ABSTRACT Drug interactions elicited through inhibition of cytochrome P450 fractions were tested for inhibition of six human P450 enzyme (P450) enzymes are important in pharmacotherapy. Recently, activities (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and greater attention has been focused on not only parent drugs CYP3A4). Observation of inhibition in fractions that correspond to inhibiting P450 enzymes but also on possible inhibition of these the retention times of metabolites indicates that the metabolite Downloaded from enzymes by circulating metabolites. In this report, an ex vivo method has the potential to contribute to P450 inhibition in vivo. Using whereby the potential for circulating metabolites to be inhibitors of this approach, norfluoxetine, hydroxyitraconazole, desmethyldiltia- P450 enzymes is described. To test this method, seven drugs and zem, desacetyldiltiazem, desethylamiodarone, hydroxybupropion, their known plasma metabolites were added to control human erythro-dihydrobupropion, and threo-dihydrobupropion were iden- plasma at concentrations previously reported to occur in humans
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Intranasal Rhinitis Agents
    Intranasal Rhinitis Agents Therapeutic Class Review (TCR) February 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected].
    [Show full text]
  • Aerobic Treatment of Selective Serotonin Reuptake Inhibitors in Landfill Leachate Ove Bergersen1*, Kine Østnes Hanssen2 and Terje Vasskog2,3
    Bergersen et al. Environmental Sciences Europe (2015) 27:6 DOI 10.1186/s12302-014-0035-0 RESEARCH Open Access Aerobic treatment of selective serotonin reuptake inhibitors in landfill leachate Ove Bergersen1*, Kine Østnes Hanssen2 and Terje Vasskog2,3 Abstract Background: Pharmaceuticals used in human medical care are not completely eliminated in the human body and can enter the municipal sewage sludge system and leachate water from landfill both as the parent compound and as their biologically active metabolites. The selective serotonin reuptake inhibitors (SSRIs) have a large potential for unwanted effects on nontarget organisms in the environment. Leachates from active or old closed landfills are often treated with continuous stirring and simple aeration in a pond/lagoon before infiltration into the environment. The aim of this work was to simulate the reduction of five SSRIs (citalopram, fluoxetine, paroxetine, sertraline and fluvoxamine) and three of their metabolites (desmethylcitalopram, didesmethylcitalopram and norfluoxetine) during aerobic treatment of leachate from landfills. This landfill leachate-simulation experiment was performed to see what happens with the pharmaceuticals during aerated treatment and continuous stirring of landfill leachate for 120 h. It is important to establish whether different pollutants such as pharmaceuticals can be removed (oxidized or otherwise degraded) or not before infiltration into the environment. Results: All the SSRIs had a significant concentration reduction during the aeration treatment process. Total SSRI concentrations were reduced significantly during aerobic treatment, and the individual SSRIs were reduced by 89% to 100% after 120 h. Among the high-concentration samples, fluoxetine (10 mg L−1) was the least degraded with 93% concentration reduction.
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • The Use of Boron-Doped Diamond Electrode for the Determination of Selected Biocides in Water Samples
    water Article The Use of Boron-Doped Diamond Electrode for the Determination of Selected Biocides in Water Samples Katarzyna Mielech-Łukasiewicz * and Barbara Starczewska Institute of Chemistry, University of Białystok, Ciołkowskiego 1 K, 15-245 Białystok, Poland * Correspondence: [email protected]; Tel.: +48-85-738-80-65 Received: 24 June 2019; Accepted: 30 July 2019; Published: 31 July 2019 Abstract: In recent years, the remains of chemical substances in water environments, referred to as emerging organic contaminations, have been more and more often studied by analysts. This work shows the possibility of using a boron-doped diamond electrode to determine low concentration levels of remains of pharmaceuticals in environmental samples. The study focused on selected biocides from the group of azole fungicides (itraconazole and posaconazole) and was performed using quick and sensitive electrochemical methods. The cyclic voltammetry method was used in order to determine the properties of these compounds, whereas analytical characterization was performed using square wave voltammetry. The work involved the specification of the optimum electrooxidation conditions of the selected fungicides, their comparative characterization, and the development of a new, sensitive methods of itraconazole and posaconazole assay. The proposed procedures allowed us to determine itraconazole in the range from 7.9 10 8 to 1.2 10 6 moL L 1 and posaconazole in the range from × − × − · − 5.7 10 8 to 8.44 10 7 moL L 1. The relative standard deviation of the measurements did not × − × − · − exceed 5.85%. The developed procedures were successfully used to determine itraconazole and posaconazole concentration in water samples and the assay recovery was between 93.5% and 102.8%.
    [Show full text]
  • THE USE of MIRTAZAPINE AS a HYPNOTIC O Uso Da Mirtazapina Como Hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa
    ARTIGO ESPECIAL THE USE OF MIRTAZAPINE AS A HYPNOTIC O uso da mirtazapina como hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa Prescription of approved hypnotics for insomnia decreased by more than 50%, whereas of antidepressive agents outstripped that of hypnotics. However, there is little data on their efficacy to treat insomnia, and many of these medications may be associated with known side effects. Antidepressants are associated with various effects on sleep patterns, depending on the intrinsic pharmacological properties of the active agent, such as degree of inhibition of serotonin or noradrenaline reuptake, effects on 5-HT1A and 5-HT2 receptors, action(s) at alpha-adrenoceptors, and/or histamine H1 sites. Mirtazapine is a noradrenergic and specific serotonergic antidepressive agent that acts by antagonizing alpha-2 adrenergic receptors and blocking 5-HT2 and 5-HT3 receptors. It has high affinity for histamine H1 receptors, low affinity for dopaminergic receptors, and lacks anticholinergic activity. In spite of these potential beneficial effects of mirtazapine on sleep, no placebo-controlled randomized clinical trials of ABSTRACT mirtazapine in primary insomniacs have been conducted. Mirtazapine was associated with improvements in sleep on normal sleepers and depressed patients. The most common side effects of mirtazapine, i.e. dry mouth, drowsiness, increased appetite and increased body weight, were mostly mild and transient. Considering its use in elderly people, this paper provides a revision about studies regarding mirtazapine for sleep disorders. KEYWORDS: sleep; antidepressive agents; sleep disorders; treatment� A prescrição de hipnóticos aprovados para insônia diminuiu em mais de 50%, enquanto de antidepressivos ultrapassou a dos primeiros.
    [Show full text]
  • Download Article (PDF)
    Use of astemizole in a large group practice TIMOTHY J. CRAIG, DO MARK GREENWALD, MD VANESSA KAUFFMANN JILL CRAIG, MS Astemizole was released in 1988. Shortly after the release of astemizole and terfe­ In late 1992, a new warning label was added nadine, it became evident that both were associat­ in response to reports of syncope and death ed with prolonged QT intervals and arrhythmias, from arrhythmia. Records of patients given new mainly torsades de pointes. Because of this associ­ prescriptions for astemizole were reviewed ation, the Food and Drug Administration (FDA) and to assess compliance with the warnings in a the manufacturers provided a warning letter to large multispecialty practice. The indication physicians in 1992.1 For astemizole, the warning was appropriate in 89% of cases. Excessive stated: (1) That arrhythmias have usually occurred doses were used in 4% of cases. Two percent when the dose of 10 mg/d (the recommended dose) of prescriptions were given to patients with was exceeded. Exceeding this dose and the use of contraindications. Only two complications loading doses should be avoided. (2) Serum levels were documented. Despite carrying a drug of astemizole may be elevated by ketoconazole, ery­ warning, astemizole continues to be used thromycin;, and itraconazole. These drugs should inappropriately and is a medicolegal concern. not be used together. (3) Presyncope and syncope Education and drug evaluations can be used may precede fatal arrhythmias and calls for dis­ to enhance compliance and decrease the risk continuing astemizole. (4) The drug should be avoid­ associated with the use of astemizole. ed in patients with significant liver disease.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]